Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› Fabry Disease (X-linked lysosomal storage disease).
Fabry Disease (X-linked lysosomal storage disease).
2 total trials
Filter these 2 trials by phase, country, sponsor and more.
Open in Search →
Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Recruitment ended
2024-512700-18-00
4
2025-04-03
A Phase I/II Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fab …
Ended
2024-512695-34-00
7
2022-06-28
Showing 1–2 of 2 trials